Search Results - "MEZZABOTTA, Mauro"
-
1
The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
Published in British journal of haematology (01-09-2018)“…Summary Erythropoiesis‐stimulating agents (ESAs) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic…”
Get full text
Journal Article -
2
Clinical Outcomes of 420 MDS Patients Treated with 5-Azacytidine: Evaluation of Overall Survival, Duration of Treatment and Rate of Discontinuation in a Real Life Study from the Italian MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM)
Published in Blood (02-12-2016)“…▪ Introduction Azacytidine(AZA) is the current standard of care for patients with high-risk myelodysplastic syndrome (MDS) in Europe. AZA has shown a survival…”
Get full text
Journal Article -
3
Serum levels of erythropoietin and soluble transferrin receptor during pregnancy in non-β-thalassemic and β-thalassemic women
Published in Haematologica (Roma) (01-09-2000)Get full text
Journal Article -
4
Phenotypes of individuals with a beta thal classical allele associated either with a beta thal silent allele or with alpha globin gene triplication
Published in Haematologica (Roma) (01-09-1997)“…Associazione Nazionale per la Lotta contro le Microcitemie in Italia, Rome. BACKGROUND AND OBJECTIVE: beta thalassemia intermedia has its origins in compound…”
Get full text
Journal Article -
5
Factors regulating Hb F synthesis in thalassemic diseases
Published in BMC blood disorders (06-02-2002)“…BACKGROUND: The thalassemic syndromes originate from mutations of the globin genes that cause, besides the characteristic clinical picture, also an increased…”
Get full text
Journal Article